{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:06:35Z","timestamp":1781258795945,"version":"3.54.1"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MASLD and sarcopenia share common pathophysiological mechanisms, including insulin resistance and chronic inflammation, and their coexistence has been associated with increased risks of hepatic fibrosis, cardiovascular events, and all-cause mortality. Mapping research trends and nutrition-related implications along the liver\u2013muscle axis may help inform precision nutrition strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>English-language original articles and reviews published from January 2012 to December 2025 were retrieved from the Web of Science Core Collection and Scopus databases. A total of 701 unique publications were included. Bibliometric analyses, including descriptive statistics, collaboration network analysis, co-citation analysis, and keyword burst detection, were performed using the R package bibliometrix, CiteSpace, and VOSviewer. BERTopic modeling was applied to identify latent semantic themes and their temporal evolution. Relevant prospective cohort studies from PubMed were also reviewed to provide contextual evidence on longitudinal associations between muscle-related parameters and MASLD outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The field grew at an average annual rate of 36.6%, with China, South Korea, and the United States forming the core collaborative network; South Korean authors showed particularly high productivity and influence. The research focus shifted from molecular mechanisms to clinical phenotyping, risk prediction, and intervention-related topics. BERTopic modeling identified three emerging themes: sarcopenia\u2013fibrosis risk, lipid metabolism with lifestyle interventions, and cardiometabolic comorbidity management. The prospective cohort studies suggested that low muscle mass and impaired muscle function were associated with a higher risk of MASLD onset or progression (HR 1.18\u20137.96), consistent with previously proposed mechanisms, including lipotoxicity, systemic inflammation, and gut\u2013liver\u2013muscle axis dysregulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Research on MASLD and sarcopenia has progressively shifted from descriptive and mechanistic studies toward early fibrosis risk prediction, lifestyle-based interventions, and integrated metabolic management. Standardized muscle assessment and further investigation of the liver\u2013muscle axis are needed to support precision nutrition strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1834112","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:53:55Z","timestamp":1781258035000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["MASLD and sarcopenia research (2012\u20132025): a multi-database bibliometric analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Keyan","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Xun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalei","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"An","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/s2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s13679-025-00637-9","article-title":"Metabolically healthy obesity and metabolic dysfunction-associated Steatotic liver disease (MASLD): navigating the controversies in disease development and progression","volume":"14","author":"Koliaki","year":"2025","journal-title":"Curr Obes Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"101544","DOI":"10.1016\/j.aohep.2024.101544","article-title":"Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"29","author":"Malik","year":"2024","journal-title":"Ann Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"155533","DOI":"10.1016\/j.metabol.2023.155533","article-title":"Epidemiology of sarcopenia: prevalence, risk factors, and consequences","volume":"144","author":"Yuan","year":"2023","journal-title":"Metabolism"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e49078","DOI":"10.7759\/cureus.49078","article-title":"Liver disease-related sarcopenia: a predictor of poor prognosis by accelerating hepatic decompensation in advanced chronic liver disease","volume":"15","author":"Nakamura","year":"2023","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/lt.25591","article-title":"Sarcopenia in chronic liver disease: impact on outcomes","volume":"25","author":"Ooi","year":"2019","journal-title":"Liver Transpl"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/nu16050658","article-title":"Implications of protein and sarcopenia in the prognosis, treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"16","author":"Singh","year":"2024","journal-title":"Nutrients"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jhep.2021.11.006","article-title":"Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis","volume":"76","author":"Tantai","year":"2022","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/jcsm.12797","article-title":"Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China","volume":"12","author":"Zeng","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/joim.20103","article-title":"Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care","volume":"298","author":"Balkhed","year":"2025","journal-title":"J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/hc9.0000000000000711","article-title":"Skeletal muscle and MASLD: mechanistic and clinical insights","volume":"9","author":"Marjot","year":"2025","journal-title":"Hepatol Commun"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/nu17010178","article-title":"Sarcopenia in MASLD-eat to beat steatosis, move to prove strength","volume":"17","author":"Cri\u015fan","year":"2025","journal-title":"Nutrients"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/hc9.0000000000000791","article-title":"Mediterranean diet and associated metabolite signatures in relation to MASLD progression: a prospective cohort study","volume":"9","author":"Wang","year":"2025","journal-title":"Hepatol Commun"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41598-020-79718-9","article-title":"Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients","volume":"11","author":"Lanthier","year":"2021","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"929459","DOI":"10.3389\/fnut.2022.929459","article-title":"Editorial: sarcopenia, frailty and nutrition in liver diseases","volume":"9","author":"Iacob","year":"2022","journal-title":"Front Nutr"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"101696","DOI":"10.1016\/j.arr.2022.101696","article-title":"Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: an altered liver-muscle crosstalk leading to increased mortality risk","volume":"80","author":"Kuchay","year":"2022","journal-title":"Ageing Res Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1739037","DOI":"10.3389\/fimmu.2026.1739037","article-title":"Structural and temporal dynamics of nano-based therapies in ulcerative colitis: history, hotspots, and emerging trends","volume":"17","author":"Shi","year":"2026","journal-title":"Front Immunol"},{"key":"ref20","first-page":"724","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5195\/jmla.2022.1434","article-title":"VOSviewer and Bibliometrix","volume":"110","author":"Arruda","year":"2022","journal-title":"J Med Libr Assoc"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1659938","DOI":"10.3389\/fimmu.2025.1659938","article-title":"Global research trends on macrophage polarization in osteoarthritis: a bibliometric analysis","volume":"16","author":"Bamahel","year":"2025","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s13098-025-01965-5","article-title":"Perilipins: key targets for regulating lipid metabolism and alleviating abnormal lipid metabolism through exercise","volume":"17","author":"Niu","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/jcsm.13460","article-title":"ADAR2 deficiency ameliorates non-alcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1","volume":"15","author":"Kung","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","article-title":"CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis","volume":"69","author":"Zhao","year":"2018","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/nu10081099","article-title":"An update on protein, leucine, Omega-3 fatty acids, and vitamin D in the prevention and treatment of sarcopenia and functional decline","volume":"10","author":"Tessier","year":"2018","journal-title":"Nutrients"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/17474124.2018.1534586","article-title":"Sarcopenia and chronic liver diseases","volume":"12","author":"Hsu","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/biomedicines10010182","article-title":"Impact of sarcopenia and Myosteatosis in non-cirrhotic stages of liver diseases: similarities and differences across Aetiologies and possible therapeutic strategies","volume":"10","author":"Cespiati","year":"2022","journal-title":"Biomedicine"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1161\/circulationaha.123.064071","article-title":"Sarcopenia and cardiovascular diseases","volume":"147","author":"Damluji","year":"2023","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12877-024-05012-2","article-title":"Associations of CBC-derived inflammatory indicators with sarcopenia and mortality in adults: evidence from Nhanes 1999\u202f\u223c\u202f2006","volume":"24","author":"Guo","year":"2024","journal-title":"BMC Geriatr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12876-025-03661-0","article-title":"Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study","volume":"25","author":"Liang","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.3350\/cmh.2022.0398","article-title":"Risk factors in nonalcoholic fatty liver disease","volume":"29","author":"Ko","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/hep.30049","article-title":"Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study","volume":"68","author":"Kim","year":"2018","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jhep.2022.01.010","article-title":"Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK biobank participants","volume":"76","author":"Petermann-Rocha","year":"2022","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/hep4.1975","article-title":"Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex","volume":"6","author":"Cho","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/jcsm.13125","article-title":"Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort","volume":"14","author":"Choe","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.cgh.2022.01.020","article-title":"Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression","volume":"21","author":"Hsieh","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"105346","DOI":"10.3748\/wjg.v31.i20.105346","article-title":"Metabolic dysfunction-associated steatotic liver disease: a story of muscle and mass","volume":"31","author":"Isakov","year":"2025","journal-title":"World J Gastroenterol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cmet.2025.12.004","article-title":"Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night","volume":"38","author":"Marjot","year":"2026","journal-title":"Cell Metab"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/nu17040663","article-title":"The influence of physical exercise, ketogenic diet, and time-restricted eating on De novo lipogenesis: a narrative review","volume":"17","author":"Paoli","year":"2025","journal-title":"Nutrients"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ijms27010060","article-title":"Inflammation-insulin resistance crosstalk and the central role of Myokines","volume":"27","author":"Dobre","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/antiox13111363","article-title":"Myokines and their potential protective role against oxidative stress in metabolic dysfunction-associated Steatotic liver disease (MASLD)","volume":"13","author":"Bucarey","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-026-05015-3","article-title":"Decoding the mechanistic basis of liver-muscle communication in health and disease","author":"Gamil","year":"2026","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1172\/jci18212","article-title":"NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis","volume":"112","author":"Bataller","year":"2003","journal-title":"J Clin Invest"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/sj.bjc.6602725","article-title":"Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia","volume":"93","author":"Sanders","year":"2005","journal-title":"Br J Cancer"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1172\/jci19246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J Clin Invest"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"E105","DOI":"10.1152\/ajpendo.00070.2021","article-title":"Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity","volume":"321","author":"Kunz","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.bbrc.2003.10.013","article-title":"Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone","volume":"311","author":"Lagathu","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1074\/jbc.M112.419788","article-title":"Interleukin-6\/signal transducer and activator of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast proliferation during muscle regeneration","volume":"288","author":"Zhang","year":"2013","journal-title":"J Biol Chem"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/nm.3656","article-title":"STAT3 signaling controls satellite cell expansion and skeletal muscle repair","volume":"20","author":"Tierney","year":"2014","journal-title":"Nat Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e2410439","DOI":"10.1002\/advs.202410439","article-title":"Liver-secreted extracellular vesicles promote cirrhosis-associated skeletal muscle injury through mtDNA-cGAS\/STING Axis","volume":"12","author":"Fan","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cmet.2025.02.009","article-title":"Remote limb ischemic conditioning alleviates steatohepatitis via extracellular vesicle-mediated muscle-liver crosstalk","volume":"37","author":"Zhao","year":"2025","journal-title":"Cell Metab"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1002\/jcsm.13342","article-title":"Altered gut microbiome, bile acid composition and metabolome in sarcopenia in liver cirrhosis","volume":"14","author":"Aliwa","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijms21155254","article-title":"Liver cirrhosis and sarcopenia from the viewpoint of Dysbiosis","volume":"21","author":"Nishikawa","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/liv.14876","article-title":"Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia","volume":"41","author":"Ponziani","year":"2021","journal-title":"Liver Int"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/apt.15372","article-title":"The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng study","volume":"50","author":"Xia","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1053\/j.gastro.2025.04.006","article-title":"PNPLA3 inhibition and Cardiometabolic risk: reassessing dyslipidemia and atherosclerotic cardiovascular disease concerns","volume":"169","author":"Guo","year":"2025","journal-title":"Gastroenterology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2016.12.020","article-title":"PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease","volume":"152","author":"Simons","year":"2017","journal-title":"Gastroenterology"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s42255-024-01177-7","article-title":"Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis","volume":"7","author":"Zhang","year":"2025","journal-title":"Nat Metab"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/hep4.1822","article-title":"TM6SF2: a novel genetic player in nonalcoholic fatty liver and cardiovascular disease","volume":"6","author":"Luo","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/cells13090781","article-title":"Nuclear mTOR signaling orchestrates transcriptional programs underlying cellular growth and metabolism","volume":"13","author":"Zhao","year":"2024","journal-title":"Cells"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1771707","DOI":"10.3389\/fgene.2026.1771707","article-title":"Molecular mechanisms underlying the lifespan and healthspan benefits of dietary restriction across species","volume":"17","author":"Fan","year":"2026","journal-title":"Front Genet"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/muscles4030026","article-title":"Mechanisms underlying muscle-related diseases and aging: insights into pathophysiology and therapeutic strategies","volume":"4","author":"Fan","year":"2025","journal-title":"Muscles"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13238-017-0409-3","article-title":"mTORC1 signaling in hepatic lipid metabolism","volume":"9","author":"Han","year":"2018","journal-title":"Protein Cell"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"116811","DOI":"10.1016\/j.celrep.2025.116811","article-title":"PDX1 phosphorylation at S61 by mTORC1 links nutrient signaling to \u03b2 cell function and metabolic disease","volume":"45","author":"Fan","year":"2026","journal-title":"Cell Rep"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms23169196","article-title":"mTOR: a potential new target in nonalcoholic fatty liver disease","volume":"23","author":"Feng","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12944-025-02741-0","article-title":"Linear association between the composite dietary antioxidant index and the prevalence of sarcopenia in metabolic dysfunction-associated steatotic liver disease","volume":"24","author":"Zhang","year":"2025","journal-title":"Lipids Health Dis"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/ijms26199625","article-title":"Diet and lifestyle interventions in metabolic dysfunction-associated fatty liver disease: a comprehensive review","volume":"26","author":"Sheikh","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"112209","DOI":"10.1016\/j.diabres.2025.112209","article-title":"Impact of physical activities in metabolic dysfunction associated steatotic liver disease, sarcopenia, and cardiovascular disease","volume":"224","author":"Han","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated Steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1161\/circulationaha.124.067676","article-title":"Muscle mass and glucagon-like Peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"101880","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol Metab"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11154-025-09967-4","article-title":"New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?","volume":"26","author":"Ryan","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"e70147","DOI":"10.1002\/jcsm.70147","article-title":"Muscle loss in obesity therapy as a therapeutic target: trial design and endpoints for regulatory discussions","volume":"16","author":"von Haehling","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/mco.0000000000001131","article-title":"Sarcopenic obesity and weight loss-induced muscle mass loss","volume":"28","author":"Caturano","year":"2025","journal-title":"Curr Opin Clin Nutr Metab Care"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1834112\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:53:58Z","timestamp":1781258038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1834112\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":78,"alternative-id":["10.3389\/fnut.2026.1834112"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1834112","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1834112"}}